Business Context and Reporting Period
Company: Adial Pharmaceuticals, Inc. (ADIL)
Filing Type: Form 8-K (Current Report)
Date of Report: August 18, 2026
Event: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard.
Key Financial Metrics
This filing does not provide specific revenue, profit, cash flow, or debt figures. The material financial metric disclosed is:
- Stockholders' Equity: Below the $2,500,000 minimum requirement for continued listing on The Nasdaq Capital Market (based on the Form 10-Q for the period ended June 30, 2026).
- Market Value of Listed Securities: Below $35 million.
- Net Income: Below $500,000 from continued operations for the most recently completed fiscal year and two of the last three fiscal years.
Material Changes
The Company received a formal Notice from Nasdaq on August 18, 2026, stating it no longer satisfies the minimum stockholders' equity requirement under Listing Rule 5550(b)(1). Additionally, the Company fails to meet the alternative quantitative standards for market value of listed securities or net income.
Guidance, Outlook, and Risks
Compliance Plan: The Company has 45 calendar days (until October 2, 2026) to submit a plan to regain compliance. If accepted, an extension of up to 180 days may be granted.
Management Strategy: The Company anticipates regaining compliance upon receiving stockholder approval to convert outstanding Series A Non-Voting Convertible Preferred Stock at the 2026 Annual Meeting of Stockholders.
Risks and Contingencies:
- No assurance can be provided that the Company will obtain necessary stockholder approvals or satisfy Nasdaq requirements.
- There is no assurance that the Compliance Plan will be accepted by Nasdaq.
- If the plan is rejected or compliance is not achieved, the Company may request a hearing before Nasdaq's Hearing Panel, but there is no assurance the Panel will grant continued listing.
- Trading on Nasdaq will continue pending the conclusion of any hearing process.
Investor Verification Checklist
- Verify the exact stockholders' equity figure reported in the Form 10-Q for the period ended June 30, 2026.
- Confirm the date and agenda of the 2026 Annual Meeting of Stockholders regarding the Series A Preferred Stock conversion.
- Monitor the submission of the Compliance Plan to Nasdaq by October 2, 2026.
- Review the Company's Form 10-K for the year ended December 31, 2025, for detailed risk factors and historical financial performance.